BR9510499B1 - antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5. - Google Patents

antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.

Info

Publication number: BR9510499B1
Authority: BR; Brazil
Prior art keywords: treatment; pct; recombinant; mediated disorders; antagonists useful
Prior art date: 1994-12-23

Application number

BRPI9510499-2A

Other languages

English (en)

Other versions

BR9510499A (pt

Inventor

Robert S Ames

Edward Robert Appelbaum

Irwin M Chaiken

Richard M Cook

Mitchell Stuart Gross

Stephen Dudley Holmes

Lynette Jane Mcmillan

Timothy Wayne Theisen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1995-12-22

Publication date

2009-05-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9510499(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/467,420 external-priority patent/US5683892A/en

1995-12-22 Application filed filed Critical

1999-03-30 Publication of BR9510499A publication Critical patent/BR9510499A/pt

2009-05-05 Publication of BR9510499B1 publication Critical patent/BR9510499B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Zoology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Otolaryngology (AREA)
Cardiology (AREA)

BRPI9510499-2A 1994-12-23 1995-12-22 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5. BR9510499B1 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US36313194A	1994-12-23	1994-12-23
US08/467,420 US5683892A (en)	1994-12-23	1995-06-06	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en)	1994-12-23	1995-06-06	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en)	1994-12-23	1995-12-22	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (2)

Publication Number	Publication Date
BR9510499A BR9510499A (pt)	1999-03-30
BR9510499B1 true BR9510499B1 (pt)	2009-05-05

Family

ID=27408594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9510499-2A BR9510499B1 (pt)	1994-12-23	1995-12-22	antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.

Country Status (22)

Country	Link
US (1)	US6129913A (pt)
EP (1)	EP0800536B1 (pt)
JP (2)	JP2001523083A (pt)
CN (1)	CN100391977C (pt)
AT (1)	ATE346867T1 (pt)
AU (1)	AU708951B2 (pt)
BR (1)	BR9510499B1 (pt)
CA (1)	CA2208503C (pt)
CZ (1)	CZ297045B6 (pt)
DE (1)	DE69535319T2 (pt)
DK (1)	DK0800536T3 (pt)
ES (1)	ES2277336T3 (pt)
FI (1)	FI119374B (pt)
HK (1)	HK1003651A1 (pt)
HU (1)	HU222992B1 (pt)
LU (1)	LU92912I2 (pt)
MX (1)	MX9704779A (pt)
NL (1)	NL300787I2 (pt)
NO (2)	NO324181B1 (pt)
NZ (1)	NZ301916A (pt)
PL (1)	PL194312B1 (pt)
WO (1)	WO1996021000A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5693323A (en) *	1994-12-23	1997-12-02	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
ES2418360T3 (es) *	1999-04-09	2013-08-13	Kyowa Hakko Kirin Co., Ltd.	Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA04009418A (es) *	2002-03-29	2005-06-08	Schering Corp	Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
US7691568B2 (en)	2002-04-09	2010-04-06	Kyowa Hakko Kirin Co., Ltd	Antibody composition-containing medicament
WO2005040199A1 (en) *	2003-10-27	2005-05-06	Medvet Science Pty Ltd	A bidentate motif and methods of use
EP1810690B1 (en) *	2004-10-28	2012-01-18	Kyowa Hakko Kirin Co., Ltd.	Anti-IL-5 receptor antibody for use in treating endometriosis.
DK2152290T3 (da)	2007-04-30	2014-08-18	Glaxosmithkline Llc	Fremgangsmåder til indgivelse af anti-il-5-antistoffer
JP4335286B2 (ja)	2008-02-08	2009-09-30	ファナック株式会社	部品保護機能を備えたロボット制御装置及びロボット制御方法
JP5917143B2 (ja)	2008-03-28	2016-05-11	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	処置方法
AU2011209713B2 (en) *	2010-01-28	2014-04-03	Glaxo Group Limited	CD127 binding proteins
US9505826B2 (en)	2010-12-22	2016-11-29	Teva Pharmaceuticals Australia Pty Ltd	Modified antibody with improved half-life
CN116474091A (zh)	2015-08-24	2023-07-25	葛兰素史密斯克莱知识产权（第2 号）有限公司	生物医药组合物
US11046782B2 (en) *	2016-03-30	2021-06-29	Musc Foundation For Research Development	Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
RU2758008C2 (ru) *	2016-12-23	2021-10-25	Сефалон, Инк.	Анти-il-5 антитела
UY37747A (es)	2017-05-26	2019-01-02	Glaxosmithkline Ip Dev Ltd	Composiciones para tratar enfermedades mediadas por interleucina 5 (il-5) y métodos relacionados
MX2020003034A (es)	2017-09-29	2020-07-22	Jiangsu Hengrui Medicine Co	Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
CN113366016B (zh) *	2018-12-12	2022-12-16	上海开拓者生物医药有限公司	抗人白细胞介素5(il-5)单克隆抗体及其应用
KR20210145187A (ko) *	2019-03-29	2021-12-01	지앙수 헨그루이 메디슨 컴퍼니 리미티드	Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8800397D0 (en) *	1988-01-08	1988-02-10	Sandoz Ltd	Improvements in/relating to organic compounds
US5096704A (en) *	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
EP0367596B1 (en) *	1988-11-03	1993-12-22	Schering Corporation	Antagonist to interleukin-5 for preventing or reducing eosinophilia
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA929328B (en) *	1991-12-02	1993-07-20	Fluor Corp	Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
EP0625201A1 (en) *	1992-02-06	1994-11-23	Schering Corporation	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) *	1992-11-05	1994-05-24	Chemo Sero Therapeut Res Inst	モノクローナル抗体
AU1289795A (en) *	1993-11-19	1995-06-06	Baylor College Of Medicine	Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
US5693323A (en) *	1994-12-23	1997-12-02	Smithkline Beecham Corporation	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) *	1999-08-19	2001-02-22	Smithkline Beecham Corporation	Sialoadhesin factor-1 agonist and antagonist antibodies

1995
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en active IP Right Grant
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
1998
- 1998-04-09 HK HK98103015A patent/HK1003651A1/xx not_active IP Right Cessation
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown
- 2015-12-18 NL NL300787C patent/NL300787I2/nl unknown

Also Published As

Publication number	Publication date
NO324181B1 (no)	2007-09-03
PL194312B1 (pl)	2007-05-31
CA2208503A1 (en)	1996-07-11
MX9704779A (es)	1997-09-30
DE69535319T2 (de)	2007-07-19
JP2008029355A (ja)	2008-02-14
WO1996021000A2 (en)	1996-07-11
BR9510499A (pt)	1999-03-30
CZ196397A3 (en)	1997-10-15
EP0800536A4 (en)	2004-12-01
NL300787I1 (pt)	2016-04-05
NO2015027I1 (no)	2015-12-18
LU92912I2 (fr)	2016-02-16
CZ297045B6 (cs)	2006-08-16
ES2277336T3 (es)	2007-07-01
NO972913L (no)	1997-08-19
EP0800536A2 (en)	1997-10-15
AU4745096A (en)	1996-07-24
FI972703A0 (fi)	1997-06-23
CN1175263A (zh)	1998-03-04
NO2015027I2 (no)	2016-01-04
HU222992B1 (hu)	2004-01-28
WO1996021000A3 (en)	1996-09-06
FI972703A (fi)	1997-08-22
ATE346867T1 (de)	2006-12-15
NZ301916A (en)	1999-05-28
HUT78055A (hu)	1999-07-28
US6129913A (en)	2000-10-10
NO972913D0 (no)	1997-06-20
JP2001523083A (ja)	2001-11-20
DE69535319D1 (de)	2007-01-11
HK1003651A1 (en)	1998-11-06
AU708951B2 (en)	1999-08-19
CA2208503C (en)	2009-12-01
DK0800536T3 (da)	2007-04-02
CN100391977C (zh)	2008-06-04
NL300787I2 (pt)	2016-04-05
FI119374B (fi)	2008-10-31
PL321088A1 (en)	1997-11-24
EP0800536B1 (en)	2006-11-29

Publication	Publication Date	Title
BR9510499B1 (pt)	2009-05-05	antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
BR0008688A (pt)	2002-01-08	Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
SE9604793D0 (sv)	1996-12-20	New polymorphs
MX9706969A (es)	1997-11-29	3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos.
BG110703A (en)	2010-10-29	PHARMACEUTICAL COMPOSITION, INCLUDING HUMAN ANTIBODIES CONNECTING HUMAN TNF ALPHA AND HIS APPLICATION
ATE510552T1 (de)	2011-06-15	Verfahren zur herstellung von sekretierte verkurzte varianten des humanen thyrotropinrezeptors
PT758241E (pt)	2002-10-31	Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses
DE69738613D1 (de)	2008-05-15	Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
EP0793660A4 (en)	1999-06-30	2-SUBSTITUTED 1,2,5-THIADIAZOLIDIN-3-ON-1,1-DIOXIDES, COMPOSITION AND THEIR USE
DE69413829D1 (de)	1998-11-12	Antiglucocorticoidsteroide zur behandlung von angststörungen
FI973221A0 (fi)	1997-08-04	1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
HK1016017A1 (en)	1999-10-22	Gonococcal anti-idiotypic antibodies and methods and compositions using them
ATE78162T1 (de)	1992-08-15	5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
DE69120287D1 (en)	1996-07-18	Aminosulfonylharnstoff-acat-inhibitoren
MX9704035A (es)	1998-02-28	1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
SE9403861D0 (sv)	1994-11-09	Novel medicinal use
MXPA01010449A (es)	2005-09-20	Composicion y metodo util para el tratamiento del colico.
ATE321863T1 (de)	2006-04-15	Diagnostischer test für von pferdearthritisvirus verursachte krankheiten

Legal Events

Date	Code	Title	Description
2004-12-07	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2005-09-06	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2006-02-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2009-01-20	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2009-07-28	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.
2013-10-08	B22O	Other matters related to patents and certificates of addition of invention: legal action concerning patent	Free format text: INPI-52400.061595/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132277-54.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: SMITHKLINE BEECHAM BIOLOGICALS S.A. , SMITHKLINE BEECHAM CORPORATION, SMITHKLINE BEECHAM P.L.C, SYNGENTA PARTICIPATIONS AG, TARGACEPT, INC.
2018-07-10	B25D	Requested change of name of applicant approved	Owner name: SMITHKLINE BEECHAM P.L.C. (GB) ; GLAXOSMITHKLINE L
2018-07-24	B25D	Requested change of name of applicant approved	Owner name: GLAXOSMITHKLINE LLC (US) ; SMITHKLINE BEECHAM LIMITED (GB) Owner name: GLAXOSMITHKLINE LLC (US) ; SMITHKLINE BEECHAM LIMI
2018-08-07	B25G	Requested change of headquarter approved	Owner name: GLAXOSMITHKLINE LLC (US) ; SMITHKLINE BEECHAM LIMI
2018-08-21	B25G	Requested change of headquarter approved	Owner name: GLAXOSMITHKLINE LLC (US) ; SMITHKLINE BEECHAM LIMI
2022-07-05	B19A	Notification of judicial decision: notification of judicial decision	Free format text: PROCESSO INPI NO 52400.129576/2014-52 NUP: 00407.004137/2019-89 (REF. 0132277-54.2013.4.02.5101) SMITHKLINE BEECHAM P.L.C. E OUTROS INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: JULGAR PROCEDENTE O PEDIDO ALTERNATIVO E DECLARAR A PARCIAL NULIDADE DAS PATENTES PI9510499-2, PI9608199-6 E DETERMINAR A CORRECAO FAZENDO CONSTAR A VIGENCIA DE 20 ANOS CONTADOS DO DEPOSITO.
2023-03-07	B19A	Notification of judicial decision: notification of judicial decision	Free format text: PROCESSO INPI NO 52400.061595/2013-93 NO CNJ 0132277-54.2013.4.02.5101 (2013.51.01.132277-2) EMBARGADO : INPI-INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL EMBARGANTE: SMITHKLINE BEECHAM P.L.C. 31A VARA FEDERAL DO RIO DE JANEIRO (01322775420134025101) DECISAO: PELO EXPOSTO, DOU PROVIMENTO A REMESSA NECESSARIA E A APELACAO, PARA JULGAR PROCEDENTE O PEDIDO ALTERNATIVO E DECLARAR A NULIDADE PARCIAL DAS PATENTES PI 9510499-2 E PI 9608199-6, E DETERMINAR A CORRECAO DE SEUS RESPECTIVOS PRAZOS DE VIGENCIA CONFORME TABELA A SEGUIR: PATENTE: PI9510499-2 - NOVO PRAZO DE VIGENCIA: 22.12.2015 PATENTE: PI9608199-6 - NOVO PRAZO DE VIGENCIA: 01.04.2016 TRANSITO EM JULGADO.